Trial Profile
A randomized, observer-blinded, active-controlled Phase 2 trial evaluating of safety and tolerability of different doses and formulations NanoFlu vaccine for Influenza-virus-infections
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2019
Price :
$35
*
At a glance
- Drugs NanoFlu vaccine-Novavax (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Novavax
- 06 Oct 2019 Status changed from recruiting to active, no longer recruiting according to results presented at the IDWeek 2019.
- 25 Sep 2018 According to a Novavax media release, the first participants has been enrolled in the trial.
- 25 Sep 2018 Status changed from planning to recruiting, according to a Novavax media release.